UNIVERSITY Of CALIFORNIA, BERKELEY SCHOOL Of PUBLIC HEALTH
UNIVERSITY of CALIFORNIA, BERKELEYSCHOOL of PUBLIC HEALTHDIVISION ofINFECTIOUS DISEASES and VACCINOLOGYORIENTATION BOOKLET2020 - 2021
Division of Infectious Diseases and Vaccinology; School of Public Health2
Division of Infectious Diseases and Vaccinology; School of Public HealthDear Infectious Diseases and Vaccinology Incoming Class 2020,On behalf of the faculty, students and staff of the Division of Infectious Diseases & Vaccinology(IDV) at UC Berkeley, we would like to welcome you enthusiastically to our program at UCBerkeley. This handbook is assembled as a resource guide for new students. Please read thisin conjunction with the School of Public Health Student Handbook (available in the SPH websiteat sph.berkeley.edu/Student Resources) and the Resources and Services for GraduateStudents at Graduate Division website at http://grad.berkeley.edu/students/Much of the information in this guide can also be found in the School website under IDVprogram sections.Our faculty and staff are here to support you and take pride in your academic success. Pleasefeel free to contact us for assistance. Wishing you a very prosperous and rewarding year ahead!Sincerely,Lee Riley, MDProfessor of Epidemiology and Infectious DiseasesChair, Division of Infectious Diseases and VaccinologySchool of Public Health
Division of Infectious Diseases and Vaccinology; School of Public HealthTable of ContentsIDV MPH Program Core Competencies. 5IDI PhD Program Core Competencies . 6Overview . 7Faculty & Staff . 8IDV Faculty . 9MPH Program Career Opportunities . 29Recent SPH MPH Job Placement Statistics . 30MPH Program Curriculum Requirements . 31MPH Program Sample of Two Year Course of Study . 333MPH Field Study Practice Requirement . 366Comprehensive Examination . 41Financial Aid . 43Courses. 45Seminar Offerings . 50Ph.D. Program Introduction . 51Ph.D. Program Admission and Curriculum . 522Ph.D. Program Sample Curriculum . 58Ph.D. Program Financial Support . 59Infectious Diseases & Immunity Ph.D. Program Graduate Group Faculty . 60Tips for Newcomers . 61The Role of a Faculty Advisor . 62Student Groups. 632020 -2021 Academic Calendar. 64General Information . 66Useful Resources . 68Faculty Advisor List 2020—2021 IDI PhD Program . 69Faculty Advisor List 2020—2021 IDV MPH Program . 70Students . 724
Division of Infectious Diseases and Vaccinology; School of Public HealthIDV MPH Program Core CompetenciesStudents completing the MPH curriculum with a concentration in InfectiousDiseases should be able to: Describe the viral, bacterial, fungal, and parasitological agents of infectious diseases ofhumans; Explain the manifestations of infectious diseases and the biological, molecular, cellular, andimmunological mechanisms of infectious disease; Identify the local, state, federal, and international agencies responsible for infectious diseasesurveillance and control and explain their roles and missions; Conduct classical and molecular analyses for the detection and characterization of infectiousdisease agents; Implement advanced diagnostic and surveillance techniques used in clinical and public healthlaboratories; Identify current public health problems in communicable diseases and describe how thesocial, behavioral, environmental, and administrative/policy components of public healthaffect infectious disease distributions; Demonstrate use of biostatistics and epidemiology in infectious disease surveillance; Critically evaluate biological and experimental designs for infectious disease research; Organize, analyze, and present scientific data in a lucid manner through oral and writtencommunication.5
Division of Infectious Diseases and Vaccinology; School of Public HealthIDI PhD Program Core CompetenciesStudents completing the Infectious Diseases and Immunity PhD curriculumshould be able to: Describe the viral, bacterial, fungal, and parasitological agents of infectious diseases ofhumans; Explain the manifestations of infectious diseases and the biological, molecular, cellular andimmunological mechanisms of infection and disease Demonstrate advanced knowledge of molecular biology, microbiology, immunology,biochemistry and cell biology Identify the local, state, federal and international agencies responsible for infectious diseasesurveillance and control and explain their roles and missions Conduct classical and molecular laboratory methods Identify current public health problems in communicable diseases and describe how thesocial, behavioral, environmental and administrative/policy components of public healthaffect infectious disease distributions Demonstrate use of biostatistics and epidemiology in infectious disease Critically evaluate biological and experimental designs for infectious disease Organize, analyze and present scientific data in a lucid manner through oral and writtencommunications Teach coursework in an area relating to infectious diseases Plan, conduct, and publish original research in the area of infectious diseases and immunity6
Division of Infectious Diseases and Vaccinology; School of Public HealthOverviewThe study of infectious diseases focuses on the interactions between infectious agents, their hosts,and the environment that may lead to disease in humans. Infectious Diseases and Vaccinology (IDV)is a multidisciplinary program. The curriculum is designed to emphasize the biology and molecularbiology of host-pathogen interactions; host immune response to infection associated with protectionor pathology; the ecology, evolution, and transmission of infectious agents, methods of laboratorybased surveillance and the epidemiology of infectious diseases.The mission of the Infectious Diseases and Vaccinology Program is to create opportunities forstudents to gain new and advanced knowledge about infectious disease agents and how they interactwith host cells, human populations, and the environment. Students learn how to design andimplement independent investigations using interdisciplinary approaches. The goal is to promotepublic health through better understanding of infectious diseases and human immunology based oninteraction of basic and translational research that contributes to the development of new diagnostics,treatment, prevention, and control of human infectious diseases.The Division of Infectious Diseases & Vaccinology offers: The professional two-year MPH degree in Infectious Diseases &Vaccinology; and The five year academic degree of the Infectious Diseases andImmunity PhD program (wet lab research).IDV Office Address:2121, Berkeley Way West Building (BWW) #5321-15, Berkeley, CA 94720-7360Email: idadmin@berkeley.eduPhone: (510) 642-2613Office hours: By appointmentWebsite: sph.berkeley.edu7
Division of Infectious Diseases and Vaccinology; School of Public HealthFaculty & StaffFacultyGertrude C. Buehring, Ph.D., Professor of GraduateSchool, Emeritus, 61A Koshland HallPeter Dailey, Ph.D., Assistant Adjunct Professor5321-13 Berkeley Way West (By appointment)pjdailey@berkeley.eduEva Harris, Ph.D., Professor of Infectious Diseases and Molecular Biology,IDI PhD program Head, 500B Li Ka Shing CenterFenyong Liu, Ph.D., Professor of Virology326 Barker HallVeronica Miller, Adjunct Professor.5321-14 Berkeley Way West (By appointment)veronicam@berkeley.eduLee W. Riley, M.D., Professor and Division Chair of Infectious Diseases &Vaccinology 500D Li Ka Shing CenterGeorge F. Sensabaugh, Professor of Graduate School, Emeritus319 Mulford HallSarah Stanley, Associate Professor, School of Public Health500C Li Ka Shing CenterJohn E.Swartzberg, M.D., Clinical Professor of Medical Virology & Microbiology, Emeritus570 University HallAffiliate Faculty:Jay Graham, PhD, MBA, MPH, Assistant Professor in Residence, Env. Health SciencesJoseph Lewnard, PhD, Assistant Professor, EpidemiologyStaffTeresa Liu, IDV Division and Program ManagerOffice: 5321-15, 2121 Berkeley Way West idadmin@berkeley.edu(CPHPL Staff)Audrey B. Cristobal, Director of Field Edu,acristobal@berkeley.eduKandis Rogers, Career & Internship Specialistkrodgers@berkeley.eduOffice: 2121 Berkeley Way West8(510) 642-2613
Division of Infectious Diseases and Vaccinology; School of Public HealthIDV FacultyGertrude Buehring, PhDFenyong Liu, PhDGeorge F. Sensabaugh,D. Crim.Eva Harris, PhDPeter J. Dailey PhD, MPHVeronica Miller, PhDLee W. Riley, M.D.Sarah Stanley, PhDJohn E. Swartzberg,M.D.Joseph Lewnard, PhDJay Graham, MPH, PhD9
Division of Infectious Diseases and Vaccinology; School of Public HealthGertrude Case Buehring, PhDProfessor of the Graduate School, Public HealthOffice: 61-A Koshland HallPhone: (510) 642 – 3870Fax: (510) 642 – 6350Email: buehring@berkeley.eduEducation:PhD - Genetics, University of California, BerkeleyCLS - Doctors Hospital (clinical laboratory scientist)BA - Biology, Stanford UniversityCurrent Courses upon request of students:PH 298,299, URAP mentoringRESEARCH INTERESTS:Viral etiology of human breast cancerBovine leukemia virus (BLV) and its possible role in causing human breast cancerDevelopment of early diagnostic tests for BLV infection and a vaccine against BLVCURRENT PROJECTS:1. How do humans become infected with BLV? Is it from cattle via bovine food products?2. Can we reduce BLV infection of humans in California by eradicating BLV from beef and dairy herds(which currently have a high rate of infection)?3. Can women infected with BLV pass the virus to their children transplacentally or through breastmilk?4. Are other human organs /cells besides breasts and blood cells infected by BLV and could the virusbe associated with cancer in these organs?5. Does infection of normal human breast cells with BLV in culture cause them to acquirecharacteristics of a malignant cell?10
Division of Infectious Diseases and Vaccinology; School of Public HealthSELECTED PUBLICATIONS:Buehring GC, Sans H. Breast Cancer Gone Viral? Review of Possible Role of Bovine Leukemia Virusin Breast Cancer, and Related Opportunities for Cancer Prevention. International Journal ofEnvironmental Research and Public Health, Dec. 27, 2019, DOI: 10.3390/ijerph17010209Buehring GC, DeLaney A, Shen HM, Chu DL, Razavian N, Schwartz DA, Demkovich CR, Bates MN.Bovine leukemia virus discovered in human blood. BMC Infectious Diseaseshttps://doi.org/10.1186/s12879-3891-9, 2019Baltzell KA, Shen HM, Krishnamurty S, Sison JD, Nuovo G, Buehring GC. Bovine leukemia viruslinked to breast cancer but not co-infection with human papilloma virus: Case-control study of womenin Texas. Cancer 124:1342-9, 2018.Buehring GC, Shen HM, Schwartz DA, Lawson, JS. Bovine leukemia virus linked to breast cancer inAustralian women and identified before breast cancer development. PLoS One, June 22, 2017,DOI:10.1371/journal.pone.0179367.Buehring GC, Shen HM, Jensen HM, Jin DL, Hudes M, Block G. Exposure to bovine leukemia virusis associated with breast cancer: A case-control study. PLoS One, Sept. 2, 2015,DOI:10.1371/journal.pone.0134304.Buehring GC, Shen HM, Jensen HM, Choi KY, Sun D: Bovine leukemia virus DNA in human breasttissue. Emerging Infectious Diseases 20 (5): 772-782, 2014.Joshi D, Buehring GC: Are viruses associated with human breast cancer? Scrutinizing the molecularevidence. Breast Cancer Research and Treatment 135 (1): 1-15, 2012.Buehring GC, Philpott SM, Choi KY: Humans have antibodies reactive with bovine leukemiavirus. AIDS Research and Human Retroviruses 19(12):1105-1113, 2003.Phillpott SM, Buehring GC: Defective DNA repair in cells infected with human T-cell leukemia / bovineleukemia virus group. Journal of the National Cancer Institute 91(11):933-942, 1999.Other interests:Member, Graduate group in Infectious Diseases and Immunology, UC BerkeleyMember, Graduate group in Endocrinology, UC Berkeley11
Division of Infectious Diseases and Vaccinology; School of Public HealthPeter J. Dailey, Ph.D., MPHAssistant Adjunct Professor of Infectious Disease & VaccinologyOffice: 5321-13, Berkeley Way West (By appointment)Email: pjdailey@berkeley.eduCourse Taught: PH 266B Zoonotic DiseasesResearch Interests: Development, evaluation, and implementation of assays for the estimation of HIV incidenceDevelopment, evaluation, and enabling access of infectious disease diagnostics in low-resourcesettingsCurrent Projects: Senior Technical Officer for the Foundation for Innovative New Diagnostics (FIND). FIND is a nonprofitorganization headquartered in Geneva, Switzerland whose mission is to drive the development andearly implementation of innovative diagnostic tests that have a high impact on patient care, diseasecontrol, and public health in low-resource settings.“HIV Incidence Assay Development Partner,” grant funded through FIND. Coordination of multipleprojects related to the development, evaluation, and implementation of HIV Incidence Assays. FIND:Measuring HIV Incidence“PanDx: A Low-cost Diagnostics Platform for Health Centers in the Developing World”: discover anddevelop a prototype affordable, easy-to-use system for health workers to rapidly diagnose diseases inresource-limited settings. Prototype assays for tuberculosis (nucleic acid assay) and HIV(immunoassay) will be developed. This project is part of the Grand Challenges in Global HealthDiagnostics initiative funded by the Bill & Melinda Gates Foundation to Stratos Product Development.Selected Publications:Peter J. Dailey, Tarek Elbeik and Mark Holodniy. Companion and complementary diagnostics forinfectious diseases. Expert Rev. Molecular Diagnostics, Peter J. Dailey, Jennifer Osborn, Elizabeth A. Ashley, Ellen Jo Baron, David A. B. Dance, DanielaFusco, Caterina Fanello, Yukari C. Manabe, Margaret Mokomane, Paul N. Newton, Belay Tessema,Chris Isaacs, and Sabine Dittrich. Defining System Requirements for Simplified Blood Culture toEnable Widespread Use in Resource-Limited Settings. Diagnostics 2019, 9, 10; doi:10.3390/diagnostics9010010Morrison CS, Homan R, Mack N, Seepolmuang P, Averill M, Taylor J, Osborn J, Dailey P, Parkin N,Ongarello S, and Mastro TD. Assays for estimating HIV incidence: updated global market assessmentand estimated economic value. Journal of the International AIDS Society 2017;20(3):e25018.Doi:10.1002/jia2.25018.12
Division of Infectious Diseases and Vaccinology; School of Public HealthMurphy, G., Pilcher, C.D., Keating, S.M., Kassanjee, R., Facente, S.N., Welte, A., Grebe, E., Marson,K., Busch, M.P., Dailey, P.J., Parkin, N., Osborn, J., Ongarello, S., Marsh, K., and Garcia-Calleja, J.M.Moving towards a reliable HIV incidence test – current status, resources available, future directionsand challenges ahead. 2016. Epidemiol. Infect. DOI: d online: 22 December 2016.Holger Becker, Richard Klemm, William Dietze, Wallace White, Nadine Hlawatsch, Susanne Freyberg,Christian Moche, Peter Dailey, and Claudia Gärtner. Modular microfluidic cartridge-based universaldiagnostic system for global health applications. 2016. Proc. SPIE 9705, Microfluidics, BioMEMS, andMedical Microsystems XIV, 970514 (March 18, 2016); doi: 10.1117/12.2217892.Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, SafiH, Blakemore R, Lan NT, Jones-López EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B,Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D. Rapid detectionof Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patienttechnology. 2010. J Clin Microbiol. 48(1):229-37.13
Division of Infectious Diseases and Vaccinology; School of Public HealthEva Harris, Ph.D.Professor of Infectious DiseasesDirector, Center for Global Public HealthInfectious Diseases and Immunity PhD Program HeadOffice: 500B Li Ka Shing CenterLab: 510D Li Ka Shing CenterPhone: (510) 642-4845Email: eharris@berkeley.eduCourses Taught: PH265: Molecular Parasitology (Fall)PH260F: Infectious Disease Research in Developing Countries (Spring)PH292/3: Doctoral Research Seminar (Spring)PH162A: Public Health Microbiology (Fall) (Team taught with Drs. Sarah Stanley and Fenyong Liu)Research Interests: Molecular virology, pathogenesis, immunology, epidemiology, clinical aspects, and control of dengue,Zika, and chikungunyaEpidemiology of influenza in tropical countriesScientific capacity building in developing countriesResearch Description:Professor Harris has developed a multidisciplinary approach to study the molecular virology,pathogenesis, immunology, epidemiology, clinical aspects, and control of dengue, Zika, andchikungunya—the most prevalent mosquito-borne diseases in humans. Her work investigates viral andhost factors that modulate disease severity and immune correlates of protection and pathogenesis,using in vitro approaches, animal models, and research involving human populations. One major focusis on studies of arboviral diesase in humans, including antibody and B cell responses and correlates ofprotection; systems immunology profiling of the innate response; and viral evolution, fitness, andintrahost diversity. Another focus is viral pathogenesis, specifically the role of NS1 protein in vascularleak and ZIKV infection of the human placenta. Her international work focuses on laboratory-basedand epidemiological studies of dengue, Zika, chikungunya, and influenza in endemic Latin Americancountries, particularly in Nicaragua, where she has been working closely with the Ministry of Health forover 30 years. Long-term collaborations include clinical, biological, and immunological studies ofsevere disease through a 20-year pediatric hospital-based study; a 15-year ongoing pediatric cohortstudy of dengue, Zika, chikungunya, and influenza transmission in Managua; and a cluster randomizedcontrolled trial of evidence-based community-derived interventions to prevent and control arboviraldiseases.Selected Publications:Katzelnick, L.C., Narvaez, C., Arguello, S., Lopez Mercado, B., Collado, D., Ampie, O., Elizondo, D.,Miranda, T., Bustos Carillo, F., Mercado, J.C., Latta, K., Schiller, A., Segovia-Chumbez, B., Ojeda, S.,Sanchez, N., Plazaola, M., Coloma, J., Halloran, M.E., Premkumar, L., Gordon, A., Narvaez, F., DeSilva, A.M., Kuan, G., Balmaseda, A., Harris, E. Zika virus infection enhances future risk of severedengue disease. Science. In press.14
Division of Infectious Diseases and Vaccinology; School of Public HealthAndrade, P., Narvekar, P., Montoya, M., Michlmayr, D., Balmaseda, A., Coloma, J., Harris, E. (2020)Primary and secondary dengue virus infections elicit similar memory B cell responses but breadth toother serotypes and cross-reactivity to Zika virus is higher in secondary dengue. J. Infect. Dis. Mar 20.pii: jiaa120. doi: 10.1093/infdis/jiaa120. [Epub ahead of print]Michlmayr, D., Kim, E.Y., Rahman, A.H., Kim-Schulze, S., Che, Y., Kalayci, S., Gümüş, Z.H., Kuan, G.,Balmaseda, A., Kasarskis, A., Wolinsky, S.M., Suaréz-Fariñas, M., Harris, E. (2020) Comprehensiveinnate immune profiling of Zika cases reveals a key role of monocytes in the acute phase of infectionand no effect of prior dengue virus infection. Cell Rep. 31(4):107569.Burger-Calderon, R.*, Bustos Carillo, F.*, Gresh, L.*, Ojeda, S., Sanchez, N., Plazaola, M., Katzelnick,L., Mercado, B.L., Monterrey, J.C., Elizondo, D., Arguello, S., Nuñez, A., Gordon, A., Balmaseda, Z.,Kuan, G., Harris, E. (2020) Age-dependent manifestations and case definitions of pediatric Zika: aprospective cohort study. Lancet Infect. 20(3):371-380.Andrade, D.V., Warnes, C., Young, E., Katzelnick, L.C., de Silva A.M., Baric, R.S., and Harris, E.(2019) Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 typespecific epitope across two populations in Asia and the Americas. Sci. Rep. 9(1):16258.Wang, C.*, Puerta-Guardo, H.*, Biering, S.B.*, Glasner, D.R., Tran, E.B., Patana, M., Gomberg, T.A.,Malvar, C., Espinosa. D.A., and Harris, E. (2019) Endocytosis of flavivirus NS1 is required for NS1mediated endothelial hyperpermeability and is abolished by a single N-glycosylation site mutation.PLoS Pathog. 5(7):e1007938. PMC6687192 (*equal contribution)Andrade, P., Gimblet-Ochieng, C., Modirian, F., Collins, M., Cárdenas, M., Katzelnick, L., Montoya, M.,Michlmayr, D., Kuan, G., Balmaseda, A., Coloma, J., de Silva, A., Harris, E. (2019) Impact of preexisting dengue immunity on human antibody and memory B cell responses to Zika. Nat. Commun.10(1):938. doi: 10.1038/s41467-019-08845-3.Puerta-Guardo, H.*, Glasner, D.R.*, Espinosa, D.A., Biering, S.B., Patana, M., Ratnasiri, K., Wang,C., Beatty, P.R., and Harris, E. (2019) Flavivirus nonstructural protein 1 triggers tissue-specificvascular endothelial dysfunction reflecting disease tropism. Cell Rep. 26:1598-1613. *Co-first authors.Gordon, A., Gresh, L., Ojeda, S., Katzelnick, L., Sanchez, N., Mercado, J., Chowell, G., Lopez, B.,Elizondo, D., Coloma, J., Burger-Calderon, R., Kuan, G., Balmaseda, A., Harris, E. (2019) Priordengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. PLoS Med. 16(1):e1002726.Montoya, M., Collins, M., Dejnirattisai, W., Katzelnick, L.C., Puerta-Guardo, H., Jadi, R., Schildhauer,S., Supasa, P., Vasanawathana, S., Malasit, P., Mongkolsapaya, J., de Silva, A.D., Tissera, H.,Balmaseda, A., Screaton, G., de Silva, A.M., Harris, E. (2018) Longitudinal analysis of antibody crossneutralization following Zika and dengue virus infection in Asia and the Americas. J. Infect. Dis.218(4):536-545.Katzelnick, L.C.*, Ben-Shachar, R.*, Mercado, J.C., Rodriguez-Barraquer, I., Elizondo, D., Arguello, S.,Nuñez, A., Ojeda, S., Sanchez, N., Lopez Mercado, B., Gresh, L., Burger-Calderon, R., Kuan, G.,Gordon, A., Balmaseda, A., Harris, E. (2018) Dynamics and determinants of the force of infection ofdengue virus from 1994-2015 in Managua, Nicaragua. Proc. Natl. Acad. Sci. USA. 115(42):1076210767.Zambrana, J.V.*, Bustos, F.*, Burger-Calderon, R., Collado, D., Jairo, Sanchez, N., Ojeda, S.,Plazaola, M., Lopez, B., Arguello, S., Elizondo, D., Aviles, W., Kuan, G., Balmaseda, A., Gordon, A.,Harris, E. (2018) Seroprevalence, risk factor, and spatial analysis of Zika virus infection after the 2016epidemic in Managua, Nicaragua. Proc. Natl. Acad. Sci. USA. 115(37):9294-9299.Burger-Calderon, R., Gonzalez, K., Ojeda, S., Zambrana, J.V., Sanchez, N., Cerpas Cruz, C., SuazoLaguna, H., Bustos, F., Plazaola, M., Lopez Mercado, B., Elizondo, D., Arguello, S., Carey Monterrey,J., Nuñez, A., Coloma, J., Waggoner, J.J., Gordon, A., Kuan, G., Balmaseda, A., Harris, E. (2018)Zika virus infection in Nicaraguan households. PloS Negl. Inf. Dis. 12(5):e0006518. PMID: 2985196815
Division of Infectious Diseases and Vaccinology; School of Public HealthKatzelnick., L. Gresh, L, Halloran, M.E., Mercado, J.C., Kuan, G., Gordon, A., Balmaseda, A., andHarris, E. (2017) Antibody-dependent enhancement of severe dengue disease in humans. Science.358(6365):929-932.Glasner, D.R., Ratnasiri, K., Puerta-Guardo, H., Beatty, P.R., and Harris, E. (2017) Dengue virus NS1cytokine-independent vascular leak is dependent on endothelial glycocalyx components. PLoS Pathog.13(11):e1006673.Parameswaran, P.*, Wang, C.*, Trivedi, S.B., Eswarappa, M., Montoya, M., Balmaseda, A., andHarris, E. (2017) Intrahost selection pressures drive rapid dengue virus microevolution in acute humaninfections. Cell Host Microbe. 22(3):400-410.e5.Michlmayr, D., Andrade, P., Gonzalez, K., Balmaseda, A., and Harris E. (2017) CD14 CD16 monocytes are the main targets of Zika virus infection in peripheral blood mononuclear cells in apaediatric study in Nicaragua. Nat Microbiol. 2(11):1462-1470. PMC5997390Other interests: President, Sustainable Sciences InstituteDirector, Center for Global Public HealthInfectious Diseases and Immunity Graduate Group (Chair)Microbial Biology Graduate Group16
Division of Infectious Diseases and Vaccinology; School of Public HealthFenyong Liu, Ph.D.Professor of VirologyOffice: 326 Barker HallPhone: (510) 643-2436Fax: (510) 643-9955E-mail: liu fy@berkeley.eduCourses Taught:PH 162A: Public Health Microbiology (Fall, Team-Taught with Harris and Stanley)PH 162L: Public Health Microbiology lab (Fall)PH 264: Current Issues in Infectious Diseases (Fall)Research Interests: Biology of human viruses (e.g. herpes, cytomegalovirus)Development of novel antiviral agentsBiochemistry of nucleic acids and RNA enzymesSelected Publications:Deng, Q., Liu, Y., Li, X., Yan, B., Sun, X., Tang, W., Trang, P., Yang, Z., Gong, H., Wang, Y., Lu, J.,Chen, J., Xia, C., Xiwen X., Lu, S., Liu, F. (2019). Inhibition of human cytomegalovirus major capsidprotein expression and replication by ribonuclease P-associated external guide sequences. RNA.25(5), 645-655.To, A., Bai, Y., Shen, A., Gong, H., Umamoto, S., and Liu, F. (2011). Yeast two hybrid analyses revealnovel binary interactions between human cytomegalovirus-encoded virion proteins. PLoS ONE. 6,e17796.Bai, Y., Gong, H., Li, H.,Vu, G., Lu, S., and Liu, F. (2011). Oral delivery of RNase P ribozymes bySalmonella effectively inhibits viral infection in mice. Proc. Natl. Acad. Sci. USA. 108(8):3222-27.Jiang, X., Bai, Y., Rider, P., Kim, K., Zhang, C., Lu, S., and Liu, F. (2011). Engineered external guidesequences effectively block viral gene expression and replication in cultured cells. J. Biol.Chem. 286(1):322-30.Liu, F., and Altman, S. (2010) Ribonuclease P. Springer, New York.Bai, Y., Li, H., Gong, H., Vu, G., Umamoto, S., Zhou, T., Lu, S., Liu, F. (2010) Salmonella-mediateddelivery of RNase P ribozymes for inhibition of viral gene expression and replication in humancells. Proc. Natl. Acad. Sci. U.S.A. 107, 7269-7274.Rider, P. J., Dunn, W., Yang, E., and Liu, F. (2009). Human cytomegalovirus microRNAs. Curr TopMicrobiol Immunol, 325, 21-39.17
Division of Infectious Diseases and Vaccinology; School of Public HealthVeronica Miller, Ph.D.Adjunct ProfessorExecutive Director, Forum forCollaborative HIV ResearchPhone: (202) 974-6290Fax: (202) 872-4316E-mail: veronicam@berkeley.eduEducation:Postdoctoral - Virology, University of California, Los AngelesPostdoctoral - Cell Biology, University of New MexicoPhD - Immunology, University of ManitobaBSc - Microbiology, University of ManitobaCourse Taught:PH 236: U.S. Food and Drug Administration, Drug Development, Public Health, and Health PolicyResearch Interests: Advancing regulatory science for unmet medical/public health needsCollaborative frameworks for drug developmentTranslating biomedical innovation to global accessDisease areas: HIV, HCV, HBV, CMV, liver diseasesResearch Description:In 2001, Miller joined the Forum for Collaborative Research—a public/private partnership addressingcutting-edge science and policy issues through a process of stakeholder engagement anddeliberation—as executive director. The Forum brings together researchers and advocates, nationaland international regulatory agencies, pharmaceutical and diagnostic companies, health careproviders, and private foundations to compare data and debate consequences. The Forum alsoidentifies gaps and impediments, frames issues, an
Division of Infectious Diseases and Vaccinology; School of Public Health Gertrude Case Buehring, PhD Professor of the Graduate School, Public Health Office: 61-A Koshland Hall Phone: (510) 642 - 3870 Fax: (510) 642 - 6350 Email: buehring@berkeley.edu Education: PhD - Genetics, University of California, Berkeley
Berkeley Haas is published three times a year by the Haas School of Business, University of California, Berkeley. Address changes: alumni@haas.berkeley.edu Contact: letters@haas.berkeley.edu Berkeley Haas Magazine, UC Berkeley 2001 Addison St., Ste. 240 Berkeley, CA 94704 SUMMER 2020 How does your salary compare to salaries of fellow alums? PAGE 55
berkeley berkeley lab 15 47 8/11/1994 cl berkeley bldg. 64 25 4/8/1997 gp/cl berkeley lbl 60 60 7/23/1997 berkeley near university 7 21.5 7/1/1999 land fill berkeley san pablo 20 30 03/27/92 cl sw berkeley uclbnl 23 25 12/30/1998 cl berkeley uclbnl 15 16 11/21/91 cl
Gilad Katz Eui Chul Richard Shin Dawn Song University of California, Berkeley University of California, Berkeley University of California, Berkeley giladk@berkeley.edu ricshin@berkeley.edu dawnsong@cs.berkeley.edu Abstract—Feature generation is one of the challenging aspects of
Byung-Gon Chun bgchun@cs.berkeley.edu Kamalika Chaudhuri y kamalika@cs.berkeley.edu Hoeteck Wee z hoeteck@cs.berkeley.edu Marco Barreno x barreno@cs.berkeley.edu Christos H. Papadimitriou y christos@cs.berkeley.edu John Kubiatowicz kubitron@cs.berkeley.edu Computer Science Division University of California, Berkeley ABSTRACT
California, Berkeley. For May 6-10, 2013 further information, contact: Berkeley-Haas Magazine Editor Haas School of Business University of California Berkeley, CA 94720-1900 510-643-0259 rkelly@haas.berkeley.edu Berkeley-Haas Winter 2013, Number 82. For change of address, email alumni@haas.berkeley.edu. U
University of California, Berkeley Department of Psychology 3210 Tolman Hall Berkeley, CA 94720 (510) 555-3175 pblass@berkeley.edu Sylvia Nunez Tutoring Programs Coordinator Berkeley Tutoring Center 695 College Ave. Berkeley, CA 92431 (510) 555-4892
Nov 04, 2012 · §Materials Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States Berkeley Sensor and Actuator Center, University of California, Berkeley, California 94720, United States *S Supp
Bridges—Curriculum Vitae 1 Khiara M. Bridges 441 North Addition UC Berkeley School of Law . Berkeley, CA 94720-7200 (646) 489-7383 . khiara.m.bridges@berkeley.edu . Academic Positions: University of California, Berkeley School of Law Professor of Law, July 2019 – present
